Greenlee JE (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1090. https://doi.org/10.1136/jnnp.2004.038489

Article  CAS  PubMed  PubMed Central  Google Scholar 

Graus F, Vogrig A, Muñiz-Castrillo S, Antoine JCG, Desestret V, Dubey D, Giometto B, Irani SR, Joubert B, Leypoldt F, McKeon A, Prüss H, Psimaras D, Thomas L, Titulaer MJ, Vedeler CA, Verschuuren JJ, Dalmau J, Honnorat J (2021) Updated diagnostic criteria for paraneoplastic neurologic syndromes. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000001014

Article  PubMed  PubMed Central  Google Scholar 

Darnell RB, Posner JB (2003) Paraneoplastic syndromes involving the nervous system. N Engl J Med 349:1543–1554. https://doi.org/10.1056/NEJMra023009

Article  CAS  PubMed  Google Scholar 

Hébert J, Riche B, Vogrig A, Muñiz-Castrillo S, Joubert B, Picard G, Rogemond V, Psimaras D, Alentorn A, Berzero G, Desestret V, Rabilloud M, Honnorat J (2020) Epidemiology of paraneoplastic neurologic syndromes and autoimmune encephalitides in France. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000883

Article  PubMed  PubMed Central  Google Scholar 

Chan AM, Baehring JM (2019) Paraneoplastic neurological syndromes: a single institution 10-year case series. J Neurooncol 141:431–439. https://doi.org/10.1007/s11060-018-03053-3

Article  PubMed  Google Scholar 

Lorusso L, Precone V, Ferrari D, Ngonga GK, Russo AG, Paolacci S, Bertelli M (2020) Paraneoplastic neurological syndromes: study of prevalence in a province of the Lombardy Region, Italy. J Clin Med. https://doi.org/10.3390/jcm9103105

Article  PubMed  PubMed Central  Google Scholar 

Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G (2010) Paraneoplastic neurologic syndrome in the PNS Euronetwork database: a European study from 20 centers. Arch Neurol 67:330–335. https://doi.org/10.1001/archneurol.2009.341

Article  PubMed  Google Scholar 

Kanikannan MA, Sirisha Y, Uppin MS, Jabeen SA, Kandadai RM, Sundaram C, Raghunadharao D, Borgohain R (2015) Incidence and spectrum of paraneoplastic neurological syndromes: single center study. J Neurooncol 125:197–206. https://doi.org/10.1007/s11060-015-1898-7

Article  PubMed  Google Scholar 

Sharma P, Goswami S, Raychaudhuri D, Siddiqui BA, Singh P, Nagarajan A, Liu J, Subudhi SK, Poon C, Gant KL, Herbrich SM, Anandhan S, Islam S, Amit M, Anandappa G, Allison JP (2023) Immune checkpoint therapy-current perspectives and future directions. Cell 186:1652–1669. https://doi.org/10.1016/j.cell.2023.03.006

Article  CAS  PubMed  Google Scholar 

Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158–168. https://doi.org/10.1056/NEJMra1703481

Article  CAS  PubMed  Google Scholar 

Yshii LM, Hohlfeld R, Liblau RS (2017) Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 13:755–763. https://doi.org/10.1038/nrneurol.2017.144

Article  CAS  PubMed  Google Scholar 

Marini A, Bernardini A, Gigli GL, Valente M, Muñiz-Castrillo S, Honnorat J, Vogrig A (2021) Neurologic adverse events of immune checkpoint inhibitors: a systematic review. Neurology 96:754–766. https://doi.org/10.1212/wnl.0000000000011795

Article  CAS  PubMed  Google Scholar 

Farina A, Villagrán-García M, Vogrig A, Zekeridou A, Muñiz-Castrillo S, Velasco R, Guidon AC, Joubert B, Honnorat J (2024) Neurological adverse events of immune checkpoint inhibitors and the development of paraneoplastic neurological syndromes. Lancet Neurol 23:81–94. https://doi.org/10.1016/s1474-4422(23)00369-1

Article  CAS  PubMed  Google Scholar 

Vogrig A, Fouret M, Joubert B, Picard G, Rogemond V, Pinto AL, Muñiz-Castrillo S, Roger M, Raimbourg J, Dayen C, Grignou L, Pallix-Guyot M, Lannoy J, Ducray F, Desestret V, Psimaras D, Honnorat J (2019) Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000000604

Article  PubMed  PubMed Central  Google Scholar 

Farina A, Villagrán-García M, Ciano-Petersen NL, Vogrig A, Muñiz-Castrillo S, Taillandier L, Michaud M, Lefilliatre M, Wang A, Lepine Z, Picard G, Wucher V, Dhairi M, Fabien N, Goncalves D, Rogemond V, Joubert B, Honnorat J (2023) Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/nxi.0000000000200058

Article  PubMed  PubMed Central  Google Scholar 

Graus F, Dalmau J (2019) Paraneoplastic neurological syndromes in the era of immune-checkpoint inhibitors. Nat Rev Clin Oncol 16:535–548. https://doi.org/10.1038/s41571-019-0194-4

Article  CAS  PubMed  Google Scholar 

Duong SL, Prüss H (2022) Paraneoplastic autoimmune neurological syndromes and the role of immune checkpoint inhibitors. Neurotherapeutics 19:848–863. https://doi.org/10.1007/s13311-022-01184-0

Article  PubMed  PubMed Central  Google Scholar 

Vogrig A, Ferrari S, Tinazzi M, Manganotti P, Vattemi G, Monaco S (2015) Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma. J Neurol Sci 350:105–106. https://doi.org/10.1016/j.jns.2015.01.028

Article  PubMed  Google Scholar 

Williams TJ, Benavides DR, Patrice KA, Dalmau JO, De Ávila ALR, Le DT, Lipson EJ, Probasco JC, Mowry EM (2016) Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 73:928–933. https://doi.org/10.1001/jamaneurol.2016.1399

Article  PubMed  Google Scholar 

Raskin J, Masrori P, Cant A, Snoeckx A, Hiddinga B, Kohl S, Janssens A, Cras P, Van Meerbeeck JP (2017) Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody. Lung Cancer 109:74–77. https://doi.org/10.1016/j.lungcan.2017.05.002

Article  PubMed  Google Scholar 

Hottinger AF, de Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R (2018) Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm 5:e439. https://doi.org/10.1212/nxi.0000000000000439

Article  PubMed  PubMed Central  Google Scholar 

Fellner A, Makranz C, Lotem M, Bokstein F, Taliansky A, Rosenberg S, Blumenthal DT, Mandel J, Fichman S, Kogan E, Steiner I, Siegal T, Lossos A, Yust-Katz S (2018) Neurologic complications of immune checkpoint inhibitors. J Neurooncol 137:601–609. https://doi.org/10.1007/s11060-018-2752-5

Article  CAS  PubMed  Google Scholar 

Matsuoka H, Kimura H, Koba H, Tambo Y, Ohkura N, Hara J, Sone T, Kasahara K (2018) Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung. Clin Lung Cancer 19:e597–e599. https://doi.org/10.1016/j.cllc.2018.04.009

Article  PubMed  Google Scholar 

Kopecký J, Kubeček O, Geryk T, Slováčková B, Hoffmann P, Žiaran M, Priester P (2018) Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report. J Med Case Rep 12:262. https://doi.org/10.1186/s13256-018-1786-9

Article  PubMed  PubMed Central  Google Scholar 

Papadopoulos KP, Romero RS, Gonzalez G, Dix JE, Lowy I, Fury M (2018) Anti-hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma. Oncologist 23:118–120. https://doi.org/10.1634/theoncologist.2017-0344

Article  PubMed  Google Scholar 

Santomasso B, D’Angelo S (2018) Anti-CRMP5-associated paraneoplastic neurologic syndrome developing in a patient with metastatic merkel cell carcinoma during immune checkpoint inhibitor treatment. Neurology. https://doi.org/10.1212/WNL.90.15_supplement.P5.409

Article  Google Scholar 

Nakatani Y, Tanaka N, Enami T, Minami S, Okazaki T, Komuta K (2018) Lambert-Eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer. Case Rep Neurol 10:346–352. https://doi.org/10.1159/000494078

Article  PubMed  PubMed Central  Google Scholar 

Gill A, Perez MA, Perrone CM, Bae CJ, Pruitt AA, Lancaster E (2019) A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes. J Neuroimmunol 334:576980. https://doi.org/10.1016/j.jneuroim.2019